Northwest Biotherapeutics Mourns the Loss of Senior VP and General Counsel Les Goldman

Northwest Biotherapeutics Mourns the Loss of Les Goldman

Northwest Biotherapeutics, a prominent biotechnology firm renowned for developing personalized immune therapies, has announced the tragic passing of its Senior Vice President and General Counsel, Mr. Les Goldman. He died after suffering a stroke, a loss felt keenly across the organization and beyond.

Les Goldman was a fundamental pillar of Northwest Biotherapeutics, dedicating many years of his life to advancing the company’s mission and advocating for cancer patients. Over his extensive career, Goldman played an instrumental role in not only navigating the complex regulatory landscape surrounding biopharmaceuticals but also in ensuring the interests of shareholders and patients were prioritized. His contributions to the field of immunotherapy, particularly via the development of the company's flagship product, DCVax®, aimed at transforming treatments for solid tumor cancers, will resonate long into the future.

The company's management team has stepped in to assume Mr. Goldman’s responsibilities during this period of transition, ensuring continued focus on their groundbreaking work in personalized medicine. Northwest Biotherapeutics expressed profound gratitude for Mr. Goldman’s tireless dedication and the significant impact he has made in the lives of patients striving for better outcomes against cancer.

About Northwest Biotherapeutics

Founded with a vision to innovate cancer treatment, Northwest Biotherapeutics is at the forefront of personalized immunotherapy. The company’s DCVax products focus on utilizing dendritic cells to boost the body's immune response against cancer. This approach aims to provide a markedly more effective treatment option with fewer toxic side effects compared to traditional chemotherapy.

Currently, the company is leading several pivotal studies, such as the Phase III trial for DCVax-L, specifically targeting glioblastoma (GBM)—one of the most aggressive brain cancers prevalent today. With a focus on bringing personalized cancer therapies to market, the company has successfully completed a significant Phase III trial with 331 patients, published results in reputable journals, and is presently seeking regulatory approval in the UK.

In addition to the glioblastoma program, Northwest Biotherapeutics is also venturing into other solid tumor types with its DCVax-Direct product. This initiative aims to treat inoperable tumors, further expanding the company’s reach and potential impact in oncology.

As Northwest Biotherapeutics continues to forge ahead, the legacy of Les Goldman will undoubtedly inspire the team to persist in their quest for innovative solutions in the cancer treatment landscape. His leadership, vision, and commitment to patient care will serve as guiding principles in the company’s continued journey.

Conclusion

The passing of Mr. Goldman is a significant loss not only for Northwest Biotherapeutics but for the broader community involved in cancer research and treatment. His contributions to the field will not be forgotten, and the company remains dedicated to honoring his memory by continuing to work tirelessly in the fight against cancer.

As the company navigates this challenging time, support from both internal and external stakeholders will be pivotal in carrying forward Mr. Goldman’s vision for a future where cancer patients have access to more effective and personalized treatment options.